Strateco Resources Inc SRSIF

Energy

Strateco Resources Inc. is a mining company. The Company is engaged in uranium exploration and development. The Company's Matoush project is located in the Otish Mountains of northern Quebec, approximately 275 kilometers north of Chibougamau and over 210 kilometers northeast of Mistissini. The Matoush project consists of the Matoush, Matoush Extension and Eclat properties, as well as the Pacific-Bay-Matoush property. The Matoush project comprises approximately 590 claims covering a total area of over 31,195 hectares. The Matoush property is located approximately 275 kilometers north of Chibougamau in the Otish Mountains of northern Quebec, Canada. The Eclat property is located in the Otish Mountains of northern Quebec, immediately south of the Matoush property. The Matoush Extension property is located north, west and east of the Matoush property in the Otish Mountains, in Northern Quebec. The Pacific-Bay Matoush Property is located in the Otish Mountains in northern Quebec.

GREY:SRSIF - Post by User

Strateco Resources Inc

Bullboard Posts

Comment by MochaTwiston Sep 08, 2006 10:10am

254 Views

Post# 11334716

RE: pessimistic!

not pessimistic, but very bloody cautious! sure everyone was gung- ho earlier. it was the pump happening- or more likely mass psychology. you mention pve and hra guys. 2 years ago I talked to pve myself at the calgary resource conference and he said that emc.to was the one to hold and now, not a word about emc.to. also, I wouldn't use the hra guys as a "back-up" either. have you noticed their great reco on nuc.v lately. it was hyped to the max and yes, I got in that one as well and now holding a pretty good loss so far. if the results don't make your "knickers" wet, then you can be assured we'll be doing the nuc.v backstep in fast mode. but maybe management will just change the position of the deposit like they did at nuc.v for the next run at the sheeple. pessimistic- no, just dam well cautious. best of luck to all.

Bullboard Posts

New glaucoma treatment studied in a $3.4 billion market